Investigating how activating specific immune signals can improve cancer treatment
Official title: Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11075381 · Data updated 2026-11-12
This study is looking at a new way to help your immune system fight cancer better by using a special virus that targets cancer cells and boosts the body's natural defenses, with the goal of creating better treatments for people with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $414,184 |
| NIH project number | 5R01CA283730-02 |
| Project ID | NIH-11075381 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who have not responded well to existing immunotherapies or have specific types of tumors that are being targeted in the study.
✕Less likely to help
Patients with early-stage cancers or those who have not yet undergone immunotherapy may not benefit from this research.
What this research studies
This research focuses on enhancing the immune response against cancer by activating CD40 and type 1 interferon signaling. It aims to increase the number and effectiveness of tumor-reactive T cells, which are essential for successful cancer immunotherapy. The study utilizes a specially engineered virus that targets cancer cells while stimulating the immune system to fight tumors more effectively. By examining both murine models and cancer patients, the research seeks to develop innovative therapies that can improve outcomes for individuals with cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that significantly improve patient outcomes.
How similar studies have gone: Previous studies have shown promising results with similar approaches in enhancing anti-tumor immunity through immune activation.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Beg, Amer Aziz — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Beg, Amer Aziz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.